Physician profile
Andrew Labelle
NPI 1891905469
$3,464.11
in general payments reported to CMS, 2019-2025
19 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $131 · 2021: $478 · 2022: $1,163 · 2023: $1,145 · 2024: $108 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Travel and Lodging: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.19 |
| Travel and Lodging | $595.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,057.80 | 2022 | |
| Pulmonx Corporation | $960.98 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $668.36 | 2021-2025 | Monarch Platform |
| Janssen Pharmaceuticals, INC | $137.52 | 2019-2022 | |
| Inspire Medical Systems, INC. | $118.79 | 2020 | |
| Genzyme Corporation | $97.27 | 2023-2025 | |
| Glaxosmithkline, LLC. | $85.96 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $66.42 | 2019 | |
| Erbe USA INC | $42.59 | 2025 | Vio3 |
| Astrazeneca Pharmaceuticals LP | $40.71 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $37.99 | 2023 | Pneumovax 23, Vaxneuvance |
| Mylan Specialty L.P. | $28.86 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $27.59 | 2025 | |
| Veran Medical Technologies, INC. | $22.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $17.11 | 2023 | Fisher & Paykel Healthcare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.98 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| United Therapeutics Corporation | $7.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Labelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.